JP2011518178A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011518178A5 JP2011518178A5 JP2011505210A JP2011505210A JP2011518178A5 JP 2011518178 A5 JP2011518178 A5 JP 2011518178A5 JP 2011505210 A JP2011505210 A JP 2011505210A JP 2011505210 A JP2011505210 A JP 2011505210A JP 2011518178 A5 JP2011518178 A5 JP 2011518178A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- composition
- angiogenesis
- optionally substituted
- activation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 46
- 230000004913 activation Effects 0.000 claims 16
- 230000033115 angiogenesis Effects 0.000 claims 16
- 125000000217 alkyl group Chemical group 0.000 claims 15
- 239000003446 ligand Substances 0.000 claims 14
- 150000001875 compounds Chemical class 0.000 claims 13
- 230000001629 suppression Effects 0.000 claims 13
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 12
- 125000003545 alkoxy group Chemical group 0.000 claims 12
- 230000000694 effects Effects 0.000 claims 12
- 229910052736 halogen Inorganic materials 0.000 claims 10
- 150000002367 halogens Chemical class 0.000 claims 10
- 125000000623 heterocyclic group Chemical group 0.000 claims 10
- 238000004519 manufacturing process Methods 0.000 claims 10
- 125000001424 substituent group Chemical group 0.000 claims 10
- 239000003814 drug Substances 0.000 claims 9
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 8
- 206010012688 Diabetic retinal oedema Diseases 0.000 claims 8
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 8
- 206010028980 Neoplasm Diseases 0.000 claims 8
- 208000034038 Pathologic Neovascularization Diseases 0.000 claims 8
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 8
- 206010038933 Retinopathy of prematurity Diseases 0.000 claims 8
- 208000006011 Stroke Diseases 0.000 claims 8
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 claims 8
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims 8
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 8
- 206010064930 age-related macular degeneration Diseases 0.000 claims 8
- 201000011510 cancer Diseases 0.000 claims 8
- 201000011190 diabetic macular edema Diseases 0.000 claims 8
- 208000024908 graft versus host disease Diseases 0.000 claims 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 8
- 230000000302 ischemic effect Effects 0.000 claims 8
- 208000002780 macular degeneration Diseases 0.000 claims 8
- 208000010125 myocardial infarction Diseases 0.000 claims 8
- 125000001072 heteroaryl group Chemical group 0.000 claims 6
- 229910052739 hydrogen Inorganic materials 0.000 claims 6
- 239000001257 hydrogen Substances 0.000 claims 6
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 6
- -1 methylenedioxy Chemical group 0.000 claims 6
- 230000007170 pathology Effects 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- 239000012453 solvate Substances 0.000 claims 6
- 230000008728 vascular permeability Effects 0.000 claims 6
- 208000035473 Communicable disease Diseases 0.000 claims 5
- 108700011893 Slit homolog 2 Proteins 0.000 claims 5
- 102100027340 Slit homolog 2 protein Human genes 0.000 claims 5
- 101150085024 Slit2 gene Proteins 0.000 claims 5
- 150000001413 amino acids Chemical class 0.000 claims 5
- 125000000753 cycloalkyl group Chemical group 0.000 claims 5
- 229940079593 drug Drugs 0.000 claims 5
- 150000004677 hydrates Chemical class 0.000 claims 5
- 229910052760 oxygen Inorganic materials 0.000 claims 5
- 150000003384 small molecules Chemical class 0.000 claims 5
- 229910052717 sulfur Inorganic materials 0.000 claims 5
- 102000034257 ADP-Ribosylation Factor 6 Human genes 0.000 claims 4
- 108090000067 ADP-Ribosylation Factor 6 Proteins 0.000 claims 4
- 206010003445 Ascites Diseases 0.000 claims 4
- 208000010392 Bone Fractures Diseases 0.000 claims 4
- 208000003174 Brain Neoplasms Diseases 0.000 claims 4
- 206010050685 Cytokine storm Diseases 0.000 claims 4
- 206010017076 Fracture Diseases 0.000 claims 4
- 208000010412 Glaucoma Diseases 0.000 claims 4
- 206010018691 Granuloma Diseases 0.000 claims 4
- 206010061218 Inflammation Diseases 0.000 claims 4
- 208000002979 Influenza in Birds Diseases 0.000 claims 4
- 208000002260 Keloid Diseases 0.000 claims 4
- 206010023330 Keloid scar Diseases 0.000 claims 4
- 206010027476 Metastases Diseases 0.000 claims 4
- 206010029113 Neovascularisation Diseases 0.000 claims 4
- 206010029164 Nephrotic syndrome Diseases 0.000 claims 4
- 208000031662 Noncommunicable disease Diseases 0.000 claims 4
- 206010030113 Oedema Diseases 0.000 claims 4
- 208000008469 Peptic Ulcer Diseases 0.000 claims 4
- 208000005228 Pericardial Effusion Diseases 0.000 claims 4
- 208000002151 Pleural effusion Diseases 0.000 claims 4
- 206010035664 Pneumonia Diseases 0.000 claims 4
- 201000004681 Psoriasis Diseases 0.000 claims 4
- 208000001647 Renal Insufficiency Diseases 0.000 claims 4
- 208000017442 Retinal disease Diseases 0.000 claims 4
- 206010038923 Retinopathy Diseases 0.000 claims 4
- 206010039710 Scleroderma Diseases 0.000 claims 4
- 206010040047 Sepsis Diseases 0.000 claims 4
- 102100025490 Slit homolog 1 protein Human genes 0.000 claims 4
- 101150028561 Slit1 gene Proteins 0.000 claims 4
- 206010043189 Telangiectasia Diseases 0.000 claims 4
- 108091008605 VEGF receptors Proteins 0.000 claims 4
- 241000700647 Variola virus Species 0.000 claims 4
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 claims 4
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 4
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 4
- 125000002947 alkylene group Chemical group 0.000 claims 4
- 208000026935 allergic disease Diseases 0.000 claims 4
- 206010003246 arthritis Diseases 0.000 claims 4
- 206010064097 avian influenza Diseases 0.000 claims 4
- 230000015572 biosynthetic process Effects 0.000 claims 4
- 208000021921 corneal disease Diseases 0.000 claims 4
- 206010052015 cytokine release syndrome Diseases 0.000 claims 4
- 230000008497 endothelial barrier function Effects 0.000 claims 4
- 201000011066 hemangioma Diseases 0.000 claims 4
- 230000011132 hemopoiesis Effects 0.000 claims 4
- 125000005842 heteroatom Chemical group 0.000 claims 4
- 230000002458 infectious effect Effects 0.000 claims 4
- 230000002757 inflammatory effect Effects 0.000 claims 4
- 230000004054 inflammatory process Effects 0.000 claims 4
- 208000028867 ischemia Diseases 0.000 claims 4
- 210000001117 keloid Anatomy 0.000 claims 4
- 201000006370 kidney failure Diseases 0.000 claims 4
- 208000032839 leukemia Diseases 0.000 claims 4
- 210000004072 lung Anatomy 0.000 claims 4
- 230000005906 menstruation Effects 0.000 claims 4
- 230000002107 myocardial effect Effects 0.000 claims 4
- 230000016087 ovulation Effects 0.000 claims 4
- 208000011906 peptic ulcer disease Diseases 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 210000002826 placenta Anatomy 0.000 claims 4
- 208000004644 retinal vein occlusion Diseases 0.000 claims 4
- 230000011664 signaling Effects 0.000 claims 4
- 239000000126 substance Substances 0.000 claims 4
- 125000003107 substituted aryl group Chemical group 0.000 claims 4
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 4
- 208000011580 syndromic disease Diseases 0.000 claims 4
- 208000009056 telangiectasis Diseases 0.000 claims 4
- 230000029663 wound healing Effects 0.000 claims 4
- 206010019280 Heart failures Diseases 0.000 claims 3
- 101150018985 SLIT3 gene Proteins 0.000 claims 3
- 102100027339 Slit homolog 3 protein Human genes 0.000 claims 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 125000003118 aryl group Chemical group 0.000 claims 3
- 230000035699 permeability Effects 0.000 claims 3
- 229920001184 polypeptide Polymers 0.000 claims 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- 230000002792 vascular Effects 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- QPGYAMIHXLCFTJ-UHFFFAOYSA-N N-[4-[5-(1,3-benzodioxol-5-yl)-3-methoxy-1,2,4-triazol-1-yl]phenyl]-2-(phenylthio)acetamide Chemical compound N1=C(OC)N=C(C=2C=C3OCOC3=CC=2)N1C(C=C1)=CC=C1NC(=O)CSC1=CC=CC=C1 QPGYAMIHXLCFTJ-UHFFFAOYSA-N 0.000 claims 2
- 208000027418 Wounds and injury Diseases 0.000 claims 2
- 230000002491 angiogenic effect Effects 0.000 claims 2
- 230000000903 blocking effect Effects 0.000 claims 2
- 239000008280 blood Substances 0.000 claims 2
- 210000004369 blood Anatomy 0.000 claims 2
- 230000006378 damage Effects 0.000 claims 2
- 208000014674 injury Diseases 0.000 claims 2
- 230000009401 metastasis Effects 0.000 claims 2
- 201000003142 neovascular glaucoma Diseases 0.000 claims 2
- 238000004321 preservation Methods 0.000 claims 2
- 102000005962 receptors Human genes 0.000 claims 2
- 108020003175 receptors Proteins 0.000 claims 2
- 230000010410 reperfusion Effects 0.000 claims 2
- 108090000695 Cytokines Proteins 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 208000007201 Myocardial reperfusion injury Diseases 0.000 claims 1
- 206010063837 Reperfusion injury Diseases 0.000 claims 1
- 101150050515 Robo4 gene Proteins 0.000 claims 1
- 230000003213 activating effect Effects 0.000 claims 1
- 125000005119 alkyl cycloalkyl group Chemical group 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4558008P | 2008-04-16 | 2008-04-16 | |
| US61/045,580 | 2008-04-16 | ||
| US7388008P | 2008-06-19 | 2008-06-19 | |
| US61/073,880 | 2008-06-19 | ||
| PCT/US2009/040848 WO2009129408A2 (en) | 2008-04-16 | 2009-04-16 | Compositions and methods for treating pathologic angiogenesis and vascular permeability |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011518178A JP2011518178A (ja) | 2011-06-23 |
| JP2011518178A5 true JP2011518178A5 (enExample) | 2012-07-26 |
Family
ID=41199735
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011505210A Pending JP2011518178A (ja) | 2008-04-16 | 2009-04-16 | 病的血管形成および脈管透過性の処置用の組成物および方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20100222401A1 (enExample) |
| EP (1) | EP2262524A4 (enExample) |
| JP (1) | JP2011518178A (enExample) |
| KR (1) | KR20100133881A (enExample) |
| CN (1) | CN101687014A (enExample) |
| BR (1) | BRPI0903901A2 (enExample) |
| CA (1) | CA2693001A1 (enExample) |
| WO (1) | WO2009129408A2 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010512327A (ja) | 2006-12-11 | 2010-04-22 | ユニヴァーシティー オブ ユタ リサーチ ファウンデーション | 病的血管形成および脈管透過性の処置用の組成物および方法 |
| US8620879B2 (en) * | 2009-10-13 | 2013-12-31 | Google Inc. | Cloud based file storage service |
| US20110087603A1 (en) * | 2009-10-13 | 2011-04-14 | Google Inc. | Cloud based media player and offline media access |
| CN102233134A (zh) * | 2010-04-30 | 2011-11-09 | 中国科学院上海生命科学研究院 | Slit-robo介导的淋巴管形成及其应用 |
| US8399404B2 (en) | 2010-06-15 | 2013-03-19 | The Hospital For Sick Children | Methods and uses for inhibiting platelet coagulation |
| US10561707B2 (en) * | 2013-09-08 | 2020-02-18 | Technion Research And Development Foundation Ltd. | Semaphorin 3C variants, compositions comprising said variants and methods of use thereof in treating eye diseases |
| WO2015183989A1 (en) * | 2014-05-27 | 2015-12-03 | Navigen, Inc. | Arf6 inhibitors and methods of synthesis and use thereof |
| MX2017011170A (es) * | 2015-03-02 | 2018-04-24 | Univ Illinois | Peptidos para inhibir la angiogenesis. |
| CN105726534A (zh) * | 2016-02-17 | 2016-07-06 | 上海交通大学医学院附属仁济医院 | SecinH3在制备抑制胃酸分泌药物中的应用 |
| WO2017173327A1 (en) * | 2016-03-31 | 2017-10-05 | The Schepens Eye Research Institute, Inc. | Endomucin inhibitor as an anti-angiogenic agent |
| CN108929383B (zh) * | 2017-05-26 | 2021-10-15 | 阿思科力(苏州)生物科技有限公司 | 重组Slit2D2(C386S)-HSA融合蛋白及其在预防和/或治疗肺部炎症中的应用 |
| US11077422B2 (en) * | 2017-06-16 | 2021-08-03 | Aquablok, Ltd. | Spalling composite particles and methods of using them |
| CN108364289B (zh) * | 2018-03-02 | 2021-05-14 | 成都斯斐德科技有限公司 | Ivoct图像易损斑块自动检测方法 |
| CN108715862A (zh) * | 2018-05-28 | 2018-10-30 | 上海海洋大学 | ddx19基因缺失斑马鱼突变体的制备方法 |
| WO2021077064A1 (en) * | 2019-10-18 | 2021-04-22 | EMULATE, Inc. | Brain-chip modeling neurodegeneration and neuroinflammation in parkinson's disease |
| WO2021184059A1 (en) * | 2020-03-14 | 2021-09-23 | Newsouth Innovations Pty Limited | Treatment methods |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5480975A (en) * | 1994-02-08 | 1996-01-02 | Brigham And Women's Hospital | Induction of vascular endothelial growth factor (VEGF) by transition metals |
| US6372958B1 (en) * | 1999-05-26 | 2002-04-16 | The University Of Utah Research Foundation | Transgenic mouse with endogenous endoglin gene disruption |
| US6960651B2 (en) * | 1999-06-29 | 2005-11-01 | Millennium Pharmaceuticals, Inc. | TANGO 332 polypeptides |
| AU2001283062A1 (en) * | 2000-08-02 | 2002-02-13 | The Johns Hopkins University | Endothelial cell expression patterns |
| US7939497B2 (en) * | 2002-03-08 | 2011-05-10 | Shanghai Institutes For Biological Sciences, Cas | Detection and modulation of slit and roundabount (robo) mediated angiogenesis and uses thereof |
| EP1534318A4 (en) * | 2002-06-27 | 2009-07-01 | Univ Utah Res Found | METHOD AND COMPOSITIONS FOR MANIPULATING GUIDED NAVIGATION OF ENDOTHONE TUBES IN THE ANGIOGENESIS |
| DE102004055998A1 (de) * | 2004-11-19 | 2006-05-24 | Rheinische Friedrich-Wilhelms-Universität Bonn | Niedermolekulare Inhibitoren von Guaninnucleotid-Austauschfaktoren der Cytohesin-Familie |
| DE102006054205A1 (de) * | 2006-11-15 | 2008-05-29 | Rheinische Friedrich-Wilhelms Universität | Verwendung von Cytohesin-Inhibitoren zur chemischen Induktion von Langlebigkeit |
| JP2010512327A (ja) * | 2006-12-11 | 2010-04-22 | ユニヴァーシティー オブ ユタ リサーチ ファウンデーション | 病的血管形成および脈管透過性の処置用の組成物および方法 |
| CN102083452A (zh) * | 2008-12-12 | 2011-06-01 | 犹他大学研究基金会 | 用于促进血管屏障功能和治疗肺纤维化的组合物和方法 |
-
2009
- 2009-04-16 KR KR1020097027516A patent/KR20100133881A/ko not_active Withdrawn
- 2009-04-16 CN CN200980000518A patent/CN101687014A/zh active Pending
- 2009-04-16 JP JP2011505210A patent/JP2011518178A/ja active Pending
- 2009-04-16 EP EP09733521A patent/EP2262524A4/en not_active Withdrawn
- 2009-04-16 CA CA 2693001 patent/CA2693001A1/en not_active Abandoned
- 2009-04-16 BR BRPI0903901A patent/BRPI0903901A2/pt not_active IP Right Cessation
- 2009-04-16 WO PCT/US2009/040848 patent/WO2009129408A2/en not_active Ceased
- 2009-04-16 US US12/667,168 patent/US20100222401A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011518178A5 (enExample) | ||
| JP2020033357A5 (enExample) | ||
| ES2389258T3 (es) | Composiciones y métodos para inhibir TGF-s | |
| JP2013510125A5 (enExample) | ||
| JP2019517464A5 (enExample) | ||
| JP2019521111A5 (enExample) | ||
| JP2014193925A5 (enExample) | ||
| JP2017528486A5 (enExample) | ||
| JP2021523887A (ja) | XIIa因子インヒビター | |
| CN114026072A (zh) | 治疗特发性肺纤维化的方法 | |
| JP6579714B2 (ja) | 化合物 | |
| JP2016531871A5 (enExample) | ||
| CA2602563A1 (en) | Combinations comprising at least one direct thrombin inhibitor for the treatment of thrombosis | |
| RU2018131775A (ru) | 6-арил-4-морфолин-1-илпиридоны, пригодные для лечения рака или диабета | |
| RU2016112542A (ru) | Новые активаторы растворимой гуанилатциклазы и их применение | |
| CN113825754A (zh) | 包括甲基和三氟甲基的双取代磺酰胺类选择性bcl-2抑制剂 | |
| JP2018525371A5 (enExample) | ||
| CA3011800A1 (en) | Methods for treating cancer | |
| JP2018525425A5 (enExample) | ||
| JP2014506582A5 (enExample) | ||
| JP2021500332A5 (enExample) | ||
| CA3001789A1 (en) | Amide-substituted aromatic compounds for use in anti-angiogenic treatment | |
| RU2018101473A (ru) | Депо-препарат, содержащий сложный эфир лимонной кислоты | |
| CA2689299A1 (en) | Synergistic combination of anthranilamide pyridinureas and benzamide derivatives | |
| CA2634216A1 (en) | Thrombin receptor antagonists as prophylaxis to complications from cardiopulmonary surgery |